On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating ... on rips ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Shares of Gilead Sciences Inc. GILD rallied 1.63% to $91.69 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 2.53% to ...

Shares of Gilead Sciences Inc. GILD inched 0.42% higher to $90.22 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.23 ...

This page features the latest news about the Gilead Sciences DRC stock. FDA grants accelerated approval to Gilead's Livdelzi for PBC FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) has ...